The GBA Multimodal Study in Parkinson's Disease (NCT04101968)
Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers
🩺 Plain-English Summary (8th-Grade Level)
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (6 items).
Location: Oregon Health & Science University — Portland, Oregon
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
- PET scan (DIAGNOSTIC_TEST)
- neuroQWERTY (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- co-occurrence of other neurological disorders;
- implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
- severe claustrophobia;
- intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
- ongoing treatment with cholinergic drugs
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (3 Sites)
- Oregon Health & Science University — Portland, Oregon
- University of Washington — Seattle, Washington
- Pacific Parkinson's Research Centre | University of British Columbia — Vancouver, British Columbia
📞 Contact the Study Coordinator
Phone: (604) 822-7764
Email: jess.mckenzie@ubc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson Disease
- Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation — Tucson, Arizona
- A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations — Little Rock, Arkansas
- Investigating Inhibitory Control Networks in Parkinson's Disease — Birmingham, Alabama
- Parkinson's Disease Progression Study — Aurora, Colorado
- Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements — East Lansing, Michigan
Explore by condition: All Parkinson Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.